Peng Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Peng Cao has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Jun Liu
Department of Neurosurgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China
4 shared publicationsFuyong Li
Third Department of Neurosurgery, Liaoning Provincial People’s Hospital, Shenyang, Liaoning, China
2 shared publicationsGuobiao Liang
Department of Neurosurgery, General Hospital of the Northern Theater Command of Chinese People's Liberation Army , Shenyang , Liaoning Province , China
2 shared publicationsJiajie He
Department of Neurosurgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China
2 shared publicationsMinghao Zhou
Department of Neurosurgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China
2 shared publicationsAijing Leng
The First Affiliated Hospital of Dalian Medical University, Dalian, China
1 shared publication
Latest Publications
- Open Access
- 10 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1769002
Intracranial extramedullary relapse of acute myeloid leukemia presenting as myeloid sarcoma mimicking meningioma: a case report and literature review
Background: Myeloid sarcoma (MS) is a rare extramedullary tumor of immature myeloid cells. Intracranial MS occurring as an extramedullary relapse without concurrent systemic acute myeloid leukemia (AML), is exceptionally rare and poses a considerable diagnostic challenge due to its non-specific clinical and radiological features, often mimicking more common intracranial neoplasms like meningioma. Case presentation: We report a case of isolated intracranial MS in a 61-year-old female with a prior history of FLT3-ITD mutated AML (M2), who had been in sustained complete hematologic remission for four years. She presented with a two-week history of diminished responsiveness and apathy. Cranial MRI revealed a well-defined, homogenously enhancing left frontal mass with a dural tail sign and significant peritumoral edema, initially suggestive of a meningioma. However, diffusion-weighted imaging (DWI) demonstrated restricted diffusion. The tumor was resected. Histopathological examination revealed diffuse sheets of immature myeloid cells. Immunohistochemistry was positive for CD117, CD34, and CD68, with weak MPO expression, confirming the diagnosis of MS. Post-operatively, the patient was referred for systemic chemotherapy. Conclusion: This case illustrates that intracranial MS can be a form of extramedullary relapse in AML patients even during long-term remission and can closely mimic a meningioma radiologically. Key diagnostic clues include a prior history of AML and radiographic features such as restricted diffusion on DWI and prominent peritumoral edema. However, these findings are non-specific, and a definitive diagnosis relies on histopathological and immunohistochemical analysis. The management of MS should be based on systemic AML therapy principles rather than surgery alone. This report highlights the necessity of considering MS in the differential diagnosis of new intracranial masses in patients with a history of AML to ensure timely and appropriate treatment.
- 10 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1769002
Open AccessIntracranial extramedullary relapse of acute myeloid leukemia presenting as myeloid sarcoma mimicking meningioma: a case report and literature review
Background: Myeloid sarcoma (MS) is a rare extramedullary tumor of immature myeloid cells. Intracranial MS occurring as an extramedullary relapse without concurrent systemic acute myeloid leukemia (AML), is exceptionally rare and poses a considerable diagnostic challenge due to its non-specific clinical and radiological features, often mimicking more common intracranial neoplasms like meningioma. Case presentation: We report a case of isolated intracranial MS in a 61-year-old female with a prior history of FLT3-ITD mutated AML (M2), who had been in sustained complete hematologic remission for four years. She presented with a two-week history of diminished responsiveness and apathy. Cranial MRI revealed a well-defined, homogenously enhancing left frontal mass with a dural tail sign and significant peritumoral edema, initially suggestive of a meningioma. However, diffusion-weighted imaging (DWI) demonstrated restricted diffusion. The tumor was resected. Histopathological examination revealed diffuse sheets of immature myeloid cells. Immunohistochemistry was positive for CD117, CD34, and CD68, with weak MPO expression, confirming the diagnosis of MS. Post-operatively, the patient was referred for systemic chemotherapy. Conclusion: This case illustrates that intracranial MS can be a form of extramedullary relapse in AML patients even during long-term remission and can closely mimic a meningioma radiologically. Key diagnostic clues include a prior history of AML and radiographic features such as restricted diffusion on DWI and prominent peritumoral edema. However, these findings are non-specific, and a definitive diagnosis relies on histopathological and immunohistochemical analysis. The management of MS should be based on systemic AML therapy principles rather than surgery alone. This report highlights the necessity of considering MS in the differential diagnosis of new intracranial masses in patients with a history of AML to ensure timely and appropriate treatment.
- Open Access
- 27 November 2025
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 12, 1673961
A new method for repairing internal carotid artery rupture in skull base surgery: a case report and review of the literature
Internal carotid artery rupture during skull base surgery represents a rare yet catastrophic complication, with limited reports documented in the literature. In this article, we describe a case of ICA rupture encountered during supratentorial craniotomy for recurrent pituitary adenoma resection. The rupture was successfully managed through a novel microsurgical repair technique, achieving complete tumor resection. A 48-year-old female presented with a history of progressive visual impairment in both eyes for the past two years, 14 years after the initial pituitary adenoma resection. Reoperation was performed through the original pterional incision. During tumor dissection, sudden rupture of the right ICA occurred. Immediate cervical common carotid artery compression was applied, followed by microsurgical hemostasis using absorbable gelatin sponge and cottonoids. Temporary aneurysm clips were placed to achieve proximal flow control, allowing full exposure of the ICA rupture site. A small autologous muscle patch was used to cover the defect, and microsurgical repair was performed using a figure-of-eight suture technique. Complete hemostasis and total tumor resection were achieved. Postoperative digital subtraction angiography confirmed the patency of the ICA without stenosis, and the patient exhibited no neurological deficits postoperatively. This case combined the advantages of muscle tissue application and surgical suturing. The use of autologous muscle tissue promoted platelet aggregation, reducing tension at the rupture site and preventing further vascular tearing, while rapid suturing minimized blood loss. Additionally, the proficient collaboration and coordination with the anesthesiologist and surgical assistants were vital for controlling the intraoperative hemorrhage and ensuring prompt repair.
- 27 November 2025
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 12, 1673961
Open AccessA new method for repairing internal carotid artery rupture in skull base surgery: a case report and review of the literature
Internal carotid artery rupture during skull base surgery represents a rare yet catastrophic complication, with limited reports documented in the literature. In this article, we describe a case of ICA rupture encountered during supratentorial craniotomy for recurrent pituitary adenoma resection. The rupture was successfully managed through a novel microsurgical repair technique, achieving complete tumor resection. A 48-year-old female presented with a history of progressive visual impairment in both eyes for the past two years, 14 years after the initial pituitary adenoma resection. Reoperation was performed through the original pterional incision. During tumor dissection, sudden rupture of the right ICA occurred. Immediate cervical common carotid artery compression was applied, followed by microsurgical hemostasis using absorbable gelatin sponge and cottonoids. Temporary aneurysm clips were placed to achieve proximal flow control, allowing full exposure of the ICA rupture site. A small autologous muscle patch was used to cover the defect, and microsurgical repair was performed using a figure-of-eight suture technique. Complete hemostasis and total tumor resection were achieved. Postoperative digital subtraction angiography confirmed the patency of the ICA without stenosis, and the patient exhibited no neurological deficits postoperatively. This case combined the advantages of muscle tissue application and surgical suturing. The use of autologous muscle tissue promoted platelet aggregation, reducing tension at the rupture site and preventing further vascular tearing, while rapid suturing minimized blood loss. Additionally, the proficient collaboration and coordination with the anesthesiologist and surgical assistants were vital for controlling the intraoperative hemorrhage and ensuring prompt repair.
- Open Access
- 5 May 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1548276
Efficacy and safety of low-dose X-rays based intraoperative radiotherapy for high-grade gliomas: a single-center retrospective study
Background: Intraoperative radiotherapy (IORT) is an emerging local therapy in the surgery of intra-axial brain tumors to improve clinical outcomes and accelerate the adjuvant oncologic therapy. Despite its use in neuro-oncology, the data regarding the role of IORT in the treatment of high-grade gliomas (HGGs) is sparse. Here we reported our single-institutional evidence concerning the efficacy and safety of IORT in the management of HGGs.Methods: A total of thirty patients diagnosed with HGGs who underwent surgical treatment and IORT at our center between October 2021 and October 2023 were included. Clinical data were collected and analyzed, including surgical parameters such as the gross total resection (GTR) rate, follow-up assessments of treatment responses (Karnofsky Performance Status [KPS] scores), treatment-related complications, overall survival (OS), and subsequent therapeutic interventions. Multivariable Cox regression analyses were performed to identify independent risk factors for survival in patients with HGGs.Results: The median IORT dose was 12 Gy prescribed to the applicator surface using the INTRABEAM system. The median OS was 11.0 months (IQR: 7.8–14.3), with a 1-year survival rate of 46.7%. No severe radiation-related adverse events, such as cerebral radiation necrosis or wound-related complications, were recorded. Kaplan-Meier analyses showed that patients who received post-operative radiotherapy and chemotherapy after IORT had better clinical outcomes than those who did not. Multivariable regression analyses indicated post-operative radiotherapy was independently correlated with favorable clinical outcomes.Conclusion: Low-dose X-rays based IORT at doses of 10-12 Gy is generally safe for HGGs. Future prospective large-scale studies are needed to further evaluate the efficacy and safety of IORT with escalating doses. Even with the use of IORT, post-operative radiotherapy is essential for improving clinical outcomes of HGGs. This study provides clinical data on IORT for HGGs, which may represent a promising therapeutic approach for managing this disease.
- 5 May 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1548276
Open AccessEfficacy and safety of low-dose X-rays based intraoperative radiotherapy for high-grade gliomas: a single-center retrospective study
Background: Intraoperative radiotherapy (IORT) is an emerging local therapy in the surgery of intra-axial brain tumors to improve clinical outcomes and accelerate the adjuvant oncologic therapy. Despite its use in neuro-oncology, the data regarding the role of IORT in the treatment of high-grade gliomas (HGGs) is sparse. Here we reported our single-institutional evidence concerning the efficacy and safety of IORT in the management of HGGs.Methods: A total of thirty patients diagnosed with HGGs who underwent surgical treatment and IORT at our center between October 2021 and October 2023 were included. Clinical data were collected and analyzed, including surgical parameters such as the gross total resection (GTR) rate, follow-up assessments of treatment responses (Karnofsky Performance Status [KPS] scores), treatment-related complications, overall survival (OS), and subsequent therapeutic interventions. Multivariable Cox regression analyses were performed to identify independent risk factors for survival in patients with HGGs.Results: The median IORT dose was 12 Gy prescribed to the applicator surface using the INTRABEAM system. The median OS was 11.0 months (IQR: 7.8–14.3), with a 1-year survival rate of 46.7%. No severe radiation-related adverse events, such as cerebral radiation necrosis or wound-related complications, were recorded. Kaplan-Meier analyses showed that patients who received post-operative radiotherapy and chemotherapy after IORT had better clinical outcomes than those who did not. Multivariable regression analyses indicated post-operative radiotherapy was independently correlated with favorable clinical outcomes.Conclusion: Low-dose X-rays based IORT at doses of 10-12 Gy is generally safe for HGGs. Future prospective large-scale studies are needed to further evaluate the efficacy and safety of IORT with escalating doses. Even with the use of IORT, post-operative radiotherapy is essential for improving clinical outcomes of HGGs. This study provides clinical data on IORT for HGGs, which may represent a promising therapeutic approach for managing this disease.
- Open Access
- 15 November 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1485209
Triterpenoids from Ganoderma lucidum inhibit cytochrome P450 enzymes interfering with the metabolic process of specific clinical drugs
Background: Ganoderma lucidum (G. lucidum), which possesses various biological effects, has been widely used as traditional medicine and functional food in Asian countries, especially China. In consideration of its various biological effects on human healthcare, G. lucidum was usually used in combination with other drugs. However, the potential drug-drug interaction induced by G. lucidum through cytochrome P450 enzymes (CYPs) remain unknown.Methods: Using the in vivo activity assay of CYPs, the inhibitory effects of G. lucidum and its constituents could be evaluated. The interference of G. lucidum on the metabolic processes of clinical drugs could be investigated. The chemical constituents of G. lucidum could be identified using LC-MS. The interaction between bioactive compounds and CYPs could be proposed through in silico docking analysis and molecular dynamics.Results: The dichloromethane extract of G. lucidum could inhibit various CYP450 subtypes in vitro and interfere with the pharmacokinetics of four drugs in rats. Triterpenoids were identified as the main constituents of the dichloromethane extract by Q-TOF-MSn in preliminary analyses. Then, a triterpenoid library containing 66 compounds was established to evaluate their inhibitory effects against CYP 1A2, 2D6, 3A4, 2A6, 2B6, 2C9, and 2C19. CYP 1A2 was inhibited by most lanostane triterpenoids, indicating a strong affinity for these compounds. Among triterpenoids, compound 25 displayed a broad inhibitory effect against CYPs, except for CYP 3A4, 2D6, 2C9, and 2C19. Finally, compounds 6 and 25 exhibited interference with the metabolism of 16 drugs through the inhibition of CYPs in vitro. In silico molecular docking analyses for assaying the interaction between compound 25 and CYPs indicated that the hydrogen bonds formed between the hydroxyl groups and amino acid residues.Conclusion: G. lucidum displayed broad inhibitory effects on CYPs, with triterpenoids as the main bioactive constituents, which may induce potential drug-drug interaction. This information should be helpful for the rational use of G. lucidum in promoting human health.
- 15 November 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1485209
Open AccessTriterpenoids from Ganoderma lucidum inhibit cytochrome P450 enzymes interfering with the metabolic process of specific clinical drugs
Background: Ganoderma lucidum (G. lucidum), which possesses various biological effects, has been widely used as traditional medicine and functional food in Asian countries, especially China. In consideration of its various biological effects on human healthcare, G. lucidum was usually used in combination with other drugs. However, the potential drug-drug interaction induced by G. lucidum through cytochrome P450 enzymes (CYPs) remain unknown.Methods: Using the in vivo activity assay of CYPs, the inhibitory effects of G. lucidum and its constituents could be evaluated. The interference of G. lucidum on the metabolic processes of clinical drugs could be investigated. The chemical constituents of G. lucidum could be identified using LC-MS. The interaction between bioactive compounds and CYPs could be proposed through in silico docking analysis and molecular dynamics.Results: The dichloromethane extract of G. lucidum could inhibit various CYP450 subtypes in vitro and interfere with the pharmacokinetics of four drugs in rats. Triterpenoids were identified as the main constituents of the dichloromethane extract by Q-TOF-MSn in preliminary analyses. Then, a triterpenoid library containing 66 compounds was established to evaluate their inhibitory effects against CYP 1A2, 2D6, 3A4, 2A6, 2B6, 2C9, and 2C19. CYP 1A2 was inhibited by most lanostane triterpenoids, indicating a strong affinity for these compounds. Among triterpenoids, compound 25 displayed a broad inhibitory effect against CYPs, except for CYP 3A4, 2D6, 2C9, and 2C19. Finally, compounds 6 and 25 exhibited interference with the metabolism of 16 drugs through the inhibition of CYPs in vitro. In silico molecular docking analyses for assaying the interaction between compound 25 and CYPs indicated that the hydrogen bonds formed between the hydroxyl groups and amino acid residues.Conclusion: G. lucidum displayed broad inhibitory effects on CYPs, with triterpenoids as the main bioactive constituents, which may induce potential drug-drug interaction. This information should be helpful for the rational use of G. lucidum in promoting human health.
- 15 May 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 370, 677-690
Electrically activated polymetallic nanocrystals for long-term tumor suppression via oxygen-independent ROS generation and electro-immunotherapy
- 15 May 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 370, 677-690
Electrically activated polymetallic nanocrystals for long-term tumor suppression via oxygen-independent ROS generation and electro-immunotherapy
- 19 February 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 263 (Pt 2) , 130307
Lysosome targeting fluorescent probe for NAAA imaging and its applications in the drug development for anti-inflammatory
- 19 February 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 263 (Pt 2) , 130307
Lysosome targeting fluorescent probe for NAAA imaging and its applications in the drug development for anti-inflammatory
- Open Access
- 1 September 2023
- Published by Walter de Gruyter GmbH in Journal of Translational Internal Medicine
- Vol. 11 (3) , 203-205
Network-guided neuromodulation for epilepsy: Unveiling the pathway to personalized therapy
Article Network-guided neuromodulation for epilepsy: Unveiling the pathway to personalized therapy was published on September 1, 2023 in the journal Journal of Translational Internal Medicine (volume 11, issue 3).
- 1 September 2023
- Published by Walter de Gruyter GmbH in Journal of Translational Internal Medicine
- Vol. 11 (3) , 203-205
Open AccessNetwork-guided neuromodulation for epilepsy: Unveiling the pathway to personalized therapy
Article Network-guided neuromodulation for epilepsy: Unveiling the pathway to personalized therapy was published on September 1, 2023 in the journal Journal of Translational Internal Medicine (volume 11, issue 3).
- Open Access
- 14 August 2023
- Published by Medknow in Neural Regeneration Research
- Vol. 19 (4) , 723-724
Current controversies in glia-to-neuron conversion therapy in neurodegenerative diseases
- 14 August 2023
- Published by Medknow in Neural Regeneration Research
- Vol. 19 (4) , 723-724
Open AccessCurrent controversies in glia-to-neuron conversion therapy in neurodegenerative diseases
- Open Access
- 6 April 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (4) , 1-15
Combination treatment with FAAH inhibitors/URB597 and ferroptosis inducers significantly decreases the growth and metastasis of renal cell carcinoma cells via the PI3K-AKT signaling pathway
Ferroptosis, a nonapoptotic form of programmed cell death characterized by significant iron-dependent peroxidation of phospholipids, is regulated by cellular metabolism, redox homeostasis, and various cancer-related signaling pathways. Recently, considerable progress has been made in demonstrating the critical role of lipid metabolism in regulating ferroptosis, indicating the potential of combinational strategies for treating cancer in the future. In this study, we explored the combinational effects of lipid metabolism compounds and ferroptosis inducers on renal cell carcinoma (RCC) cells. We found potent synergy of the fatty acid amide hydrolase (FAAH) inhibitor URB597 with ferroptosis inducer (1S, 3R)-RSL3 (RSL3) in inhibiting the growth and metastasis of RCC cells both in vitro and in vivo via induction of G1 cell cycle arrest and promotion of the production of lipid peroxides, malondialdehyde (MDA), 4-hydroxynonenal (4-HNE), and cytosolic reactive oxygen species (ROS). In addition, inhibition of FAAH increased the sensitivity of RCC cells to ferroptosis. Genome-wide RNA sequencing indicated that the combination of URB597 and RSL3 has more significant effects on regulation of the expression of genes related to cell proliferation, the cell cycle, cell migration and invasion, and ferroptosis than either single agent alone. Moreover, we found that combinational treatment modulated the sensitivity of RCC cells to ferroptosis via the phosphatidylinositol 3 kinase (PI3K)-AKT signaling pathway. These data demonstrate that dual targeting of FAAH and ferroptosis could be a promising strategy for treating RCC.
- 6 April 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (4) , 1-15
Open AccessCombination treatment with FAAH inhibitors/URB597 and ferroptosis inducers significantly decreases the growth and metastasis of renal cell carcinoma cells via the PI3K-AKT signaling pathway
Ferroptosis, a nonapoptotic form of programmed cell death characterized by significant iron-dependent peroxidation of phospholipids, is regulated by cellular metabolism, redox homeostasis, and various cancer-related signaling pathways. Recently, considerable progress has been made in demonstrating the critical role of lipid metabolism in regulating ferroptosis, indicating the potential of combinational strategies for treating cancer in the future. In this study, we explored the combinational effects of lipid metabolism compounds and ferroptosis inducers on renal cell carcinoma (RCC) cells. We found potent synergy of the fatty acid amide hydrolase (FAAH) inhibitor URB597 with ferroptosis inducer (1S, 3R)-RSL3 (RSL3) in inhibiting the growth and metastasis of RCC cells both in vitro and in vivo via induction of G1 cell cycle arrest and promotion of the production of lipid peroxides, malondialdehyde (MDA), 4-hydroxynonenal (4-HNE), and cytosolic reactive oxygen species (ROS). In addition, inhibition of FAAH increased the sensitivity of RCC cells to ferroptosis. Genome-wide RNA sequencing indicated that the combination of URB597 and RSL3 has more significant effects on regulation of the expression of genes related to cell proliferation, the cell cycle, cell migration and invasion, and ferroptosis than either single agent alone. Moreover, we found that combinational treatment modulated the sensitivity of RCC cells to ferroptosis via the phosphatidylinositol 3 kinase (PI3K)-AKT signaling pathway. These data demonstrate that dual targeting of FAAH and ferroptosis could be a promising strategy for treating RCC.
- Open Access
- 24 December 2021
- Published by Wiley in Journal of Nanomaterials
- Vol. 2021, 1-11
A Nanogel with Effective Blood-Brain Barrier Penetration Ability through Passive and Active Dual-Targeting Function
Clinically, surgery assisted by chemotherapy is the most effective treatment of cancer. But from our clinical observation, the median survival of patients with glioblastoma is still not so good with only 15-16 months. The low therapeutic index is mainly due to the blood-brain barrier (BBB) which significantly hindered the chemotherapeutic drug accumulation in tumor tissue. One main composition of the BBB is astrocyte, which contains a lipophilic cell membrane, which prevents more than 98 of small-molecule drugs from entering the brain. Previously, we found that the nanogel with passive targeting function can increase the BBB penetration ability, which indicates that it could be used to overcome the above mentioned in vivo obstacles which promoted drug accumulation in the tumor. In this study, thermosensitive targeted nanogel delivery systems (DPPC) with cell-penetrating peptides (CPP) are introduced onto the particle surface for active astrocyte breaking. The hydrodynamic radius of DPPC is around 300nm, the potential is about 0-5mV, and the TEM and DLS studies further confirm its well spherical morphology and uniform distribution. The DPPC is verified as the biocompatible carriers for further application by cell viability tests. The in vitro-constructed BBB model successfully proves that DPPC can efficiently penetrate the BBB, which is attributed to both the temperature-sensitive passive targeting and the active CPP penetration. Consequently, the intracellular doxorubicin (DOX) promotes such functional DPPC at the relatively high temperature inside tumor microenvironment (TME) (42C), which obviously improves intratumor drug accumulation and tumor cell-killing effects. The dual-targeted nanogel delivery systems designed in this study provides a more effective strategy for the treatment of glioma.
- 24 December 2021
- Published by Wiley in Journal of Nanomaterials
- Vol. 2021, 1-11
Open AccessA Nanogel with Effective Blood-Brain Barrier Penetration Ability through Passive and Active Dual-Targeting Function
Clinically, surgery assisted by chemotherapy is the most effective treatment of cancer. But from our clinical observation, the median survival of patients with glioblastoma is still not so good with only 15-16 months. The low therapeutic index is mainly due to the blood-brain barrier (BBB) which significantly hindered the chemotherapeutic drug accumulation in tumor tissue. One main composition of the BBB is astrocyte, which contains a lipophilic cell membrane, which prevents more than 98 of small-molecule drugs from entering the brain. Previously, we found that the nanogel with passive targeting function can increase the BBB penetration ability, which indicates that it could be used to overcome the above mentioned in vivo obstacles which promoted drug accumulation in the tumor. In this study, thermosensitive targeted nanogel delivery systems (DPPC) with cell-penetrating peptides (CPP) are introduced onto the particle surface for active astrocyte breaking. The hydrodynamic radius of DPPC is around 300nm, the potential is about 0-5mV, and the TEM and DLS studies further confirm its well spherical morphology and uniform distribution. The DPPC is verified as the biocompatible carriers for further application by cell viability tests. The in vitro-constructed BBB model successfully proves that DPPC can efficiently penetrate the BBB, which is attributed to both the temperature-sensitive passive targeting and the active CPP penetration. Consequently, the intracellular doxorubicin (DOX) promotes such functional DPPC at the relatively high temperature inside tumor microenvironment (TME) (42C), which obviously improves intratumor drug accumulation and tumor cell-killing effects. The dual-targeted nanogel delivery systems designed in this study provides a more effective strategy for the treatment of glioma.